Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.64 |
| ▸ | CTSS | P25774 | 7/20 | 0.64 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835996 | 1.00 | CTSK (0.64) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL1951491 | 1.00 | CTSK (0.64) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL31407722 | 0.90 | CTSK (0.54) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL31230470 | 0.90 | CTSK (0.54) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL28201406 | 0.89 | CTSK (0.54) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL28201407 | 0.89 | CTSK (0.54) | CTSKCTSSPPARAPPARGCTSL | |
| Tetrahydrofuran SCHEMBL28201868 | 0.87 | CTSK (0.52) | CTSKCTSSPPARAPPARGCTSL | |
| Tetrahydrofuran SCHEMBL28201869 | 0.87 | CTSK (0.52) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL13367322 | 0.86 | CTSK (0.63) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL15695733 | 0.86 | CTSK (0.54) | CTSKCTSSPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794572-B | Total synthesis method of natural product Lucentamycin A | 上海交通大学 | 2021-10-15 | — | — | CN | claimed |
| US-20190144452-A1 | PROCESS FOR PREPARING IDELALISIB | SYNTHON B.V. (NL) | 2019-05-16 | — | — | US | claimed |
| CN-106854183-B | The preparation method of Ai Dailalisi intermediate | 山东轩德医药科技有限公司 | 2018-11-16 | — | — | CN | claimed |
| CN-108794572-A | A kind of natural products Lucentamycin A total synthesis methods | 上海交通大学 | 2018-11-13 | — | — | CN | claimed |
| CN-106854183-A | The preparation method of Ai Dailalisi intermediates | 山东轩德医药科技有限公司 | 2017-06-16 | — | — | CN | claimed |
| CN-106146352-A | Idelalisib intermediate and preparation method thereof | 上海医药工业研究院 | 2016-11-23 | — | — | CN | claimed |
| CN-104262201-A | Synthesis method of chiral optically-pure (S)-3-aminovaleric acid | UNIV JIANGXI NORMAL SCI & TECH | 2015-01-07 | — | — | CN | claimed |
| CN-104086459-A | Novel method for chiral synthesis of optical pure (S)-3-aminopentanoic acid | UNIV JIANGXI NORMAL SCI & TECH | 2014-10-08 | — | — | CN | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | NNOCARE PHARMA INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4713321-A1 | PROTACS FOR ASK1 PROTEIN DEGRADATION: PREPARATION AND USE THEREOF | Council of Scientific and Industrial Research (IN) | 2026-03-25 | — | — | EP | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
| EP-0133795-A1 | Gaba esters and gaba analogue esters | THE McLEAN HOSPITAL CORPORATION (US) | 1985-03-06 | — | — | EP | disclosed |
| WO-1985000520-A1 | GABA ESTERS AND GABA ANALOGUE ESTERS | THE MCLEAN HOSPITAL CORPORATION (US) | 1985-02-14 | — | — | WO | disclosed |
| EP-0105193-A2 | Spergualin-related compounds, processes for the preparation thereof and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-04-11 | — | — | EP | disclosed |
| US-4005194-A | NONAPEPTIDE | ABBOTT LABORATORIES (US) | 1977-01-25 | — | — | US | disclosed |
| US-4002738-A | Treatment of specified neoplasias | ABBOTT LABORATORIES (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | CTSK 2817/4885CTSS 1575/4885PPARA 3072/4885 |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | IL17A, IL2, IL23R | CTSK 2954/4885CTSS 2855/4885PPARA 1008/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | CTSK 874/4885CTSS 1006/4885PPARA 554/4885 |
| US-20190144452-A1 | PROCESS FOR PREPARING IDELALISIB | IDE, ALK, PIK3C3 | CTSK 2110/4885CTSS 2356/4885PPARA 1747/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CTSK 1920/4885CTSS 1117/4885PPARA 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.